Systemic lupus erythematosus: still a challenge for physicians (Q38866356)

7 September 2017

1 reference

title

Systemic lupus erythematosus: still a challenge for physicians (English)

1 reference

systemic lupus erythematosus

7 September 2017

1 reference

1 reference

A A Bengtsson

1

1 reference

PubMed ID

27307107

7 September 2017

L Rönnblom

series ordinal

2

1 reference

PubMed ID

27307107

7 September 2017

language of work or name

English

0 references

publication date

16 June 2016

1 reference

Journal of Internal Medicine

7 September 2017

1 reference

7 September 2017

281

1 reference

7 September 2017

52-64

1 reference

7 September 2017

1

1 reference

Molecular mechanisms of congenital heart block

7 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Mortality in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Regulated necrosis: the expanding network of non-apoptotic cell death pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Beyond apoptosis in lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

The Role of Cell Death in the Pathogenesis of SLE: Is Pyroptosis the Missing Link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Possible induction of systemic lupus erythematosus by interferon-α treatment in a patient with a malignant carcinoid tumour

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

The interferon signature in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Disease mechanisms in rheumatology--tools and pathways: plasmacytoid dendritic cells and their role in autoimmune rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Self-reactive IgE exacerbates interferon responses associated with autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Activated T cells enhance interferon-α production by plasmacytoid dendritic cells stimulated with RNA-containing immune complexes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

How does interferon-α insult the vasculature? Let me count the ways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Platelet CD154 potentiates interferon-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type I interferon system is strongly associated with vascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

B cells responses and cytokine production are regulated by their immune microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Cytokine-producing B cells: a translational view on their roles in human and mouse autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Selective Impairment of Spatial Cognition Caused by Autoantibodies to the N-Methyl-D-Aspartate Receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Functional anti-CD94/NKG2A and anti-CD94/NKG2C autoantibodies in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

The multifaceted functions of neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

A subset of patients with systemic lupus erythematosus fails to degrade DNA from multiple clinically relevant sources

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Neutrophil extracellular trap cell death requires both autophagy and superoxide generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

A revised estimate of twin concordance in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

The support of human genetic evidence for approved drug indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Immunogenetics of systemic lupus erythematosus: A comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Advances in lupus genetics and epigenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Impact of autoimmune risk alleles on the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Systematic localization of common disease-associated variation in regulatory DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Genetic and epigenetic fine mapping of causal autoimmune disease variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

An epigenome-wide association study of total serum immunoglobulin E concentration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Genome-Wide Assessment of Differential DNA Methylation Associated with Autoantibody Production in Systemic Lupus Erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Association of STAT4 polymorphism with severe renal insufficiency in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

The Expression of BAFF Is Controlled by IRF Transcription Factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Coronary heart disease in systemic lupus erythematosus is associated with interferon regulatory factor-8 gene variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Use of atorvastatin in systemic lupus erythematosus in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Reactive oxygen species deficiency induces autoimmunity with type 1 interferon signature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Lupus-associated causal mutation in neutrophil cytosolic factor 2 (NCF2) brings unique insights to the structure and function of NADPH oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Aicardi-Goutières syndrome and the type I interferonopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Risk factors for developing systemic lupus erythematosus: a case-control study in southern Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Human parvovirus B19 induced apoptotic bodies contain altered self-antigens that are phagocytosed by antigen presenting cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Drug-induced lupus erythematosus: incidence, management and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Quinidine and procainamide inhibit murine macrophage uptake of apoptotic and necrotic cells: a novel contributing mechanism of drug-induced-lupus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Moderate alcohol drinking might be protective for systemic lupus erythematosus: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Environmental influences on systemic lupus erythematosus expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Complementing the genome with an "exposome": the outstanding challenge of environmental exposure measurement in molecular epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

Treat-to-target in systemic lupus erythematosus: are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

B lymphocytes enhance interferon-α production by plasmacytoid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12529

21 January 2018

Identifiers

DOI

10.1111/JOIM.12529

1 reference

7 September 2017

1 reference

PubMed ID

27307107